Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis

M. E. Sanders, C. L. Koski, D. Robbins, M. L. Shin, M. M. Frank, Keith A Joiner

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

A quantitative enzyme-linked immunosorbent assay was used to measure the concentration of fluid-phase complement C5b-9 complexes (SC5b-9) in the cerebrospinal fluid (CSF) of 14 patients with acute monophasic Guillain-Barre Syndrome (GBS), 21 patients with multiple sclerosis (MS), and 11 patients with noninflammatory central nervous system (CNS) diseases. SC5b-9 complexes were detected in the CSF of 13 of 14 patients with acute GBS (mean, 3.08 μg/ml; range, 0 to 7.1 μg/ml) and 16 of 21 patients with MS (mean, 1.83 μg/ml; range, 0 to 7.5 μg/ml). In the control group of patients with noninflammatory CNS diseases, SC5b-9 was not detected in eight of 11 and was present in low concentrations in the remaining three patients (mean, 0.28 μg/ml; range, 0 to 1.7 μg/ml). The finding of SC5b-9 complexes in the CSF of patients with GBS and MS suggests that terminal complement components may participate in the tissue-damaging processes in these diseases.

Original languageEnglish (US)
Pages (from-to)4456-4459
Number of pages4
JournalJournal of Immunology
Volume136
Issue number12
StatePublished - 1986
Externally publishedYes

Fingerprint

Guillain-Barre Syndrome
Multiple Sclerosis
Cerebrospinal Fluid
Central Nervous System Diseases
Complement Membrane Attack Complex
Enzyme-Linked Immunosorbent Assay
Control Groups

ASJC Scopus subject areas

  • Immunology

Cite this

Sanders, M. E., Koski, C. L., Robbins, D., Shin, M. L., Frank, M. M., & Joiner, K. A. (1986). Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. Journal of Immunology, 136(12), 4456-4459.

Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. / Sanders, M. E.; Koski, C. L.; Robbins, D.; Shin, M. L.; Frank, M. M.; Joiner, Keith A.

In: Journal of Immunology, Vol. 136, No. 12, 1986, p. 4456-4459.

Research output: Contribution to journalArticle

Sanders, ME, Koski, CL, Robbins, D, Shin, ML, Frank, MM & Joiner, KA 1986, 'Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis', Journal of Immunology, vol. 136, no. 12, pp. 4456-4459.
Sanders, M. E. ; Koski, C. L. ; Robbins, D. ; Shin, M. L. ; Frank, M. M. ; Joiner, Keith A. / Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. In: Journal of Immunology. 1986 ; Vol. 136, No. 12. pp. 4456-4459.
@article{bc1e6f32796c4f988814e486d5be7ded,
title = "Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis",
abstract = "A quantitative enzyme-linked immunosorbent assay was used to measure the concentration of fluid-phase complement C5b-9 complexes (SC5b-9) in the cerebrospinal fluid (CSF) of 14 patients with acute monophasic Guillain-Barre Syndrome (GBS), 21 patients with multiple sclerosis (MS), and 11 patients with noninflammatory central nervous system (CNS) diseases. SC5b-9 complexes were detected in the CSF of 13 of 14 patients with acute GBS (mean, 3.08 μg/ml; range, 0 to 7.1 μg/ml) and 16 of 21 patients with MS (mean, 1.83 μg/ml; range, 0 to 7.5 μg/ml). In the control group of patients with noninflammatory CNS diseases, SC5b-9 was not detected in eight of 11 and was present in low concentrations in the remaining three patients (mean, 0.28 μg/ml; range, 0 to 1.7 μg/ml). The finding of SC5b-9 complexes in the CSF of patients with GBS and MS suggests that terminal complement components may participate in the tissue-damaging processes in these diseases.",
author = "Sanders, {M. E.} and Koski, {C. L.} and D. Robbins and Shin, {M. L.} and Frank, {M. M.} and Joiner, {Keith A}",
year = "1986",
language = "English (US)",
volume = "136",
pages = "4456--4459",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis

AU - Sanders, M. E.

AU - Koski, C. L.

AU - Robbins, D.

AU - Shin, M. L.

AU - Frank, M. M.

AU - Joiner, Keith A

PY - 1986

Y1 - 1986

N2 - A quantitative enzyme-linked immunosorbent assay was used to measure the concentration of fluid-phase complement C5b-9 complexes (SC5b-9) in the cerebrospinal fluid (CSF) of 14 patients with acute monophasic Guillain-Barre Syndrome (GBS), 21 patients with multiple sclerosis (MS), and 11 patients with noninflammatory central nervous system (CNS) diseases. SC5b-9 complexes were detected in the CSF of 13 of 14 patients with acute GBS (mean, 3.08 μg/ml; range, 0 to 7.1 μg/ml) and 16 of 21 patients with MS (mean, 1.83 μg/ml; range, 0 to 7.5 μg/ml). In the control group of patients with noninflammatory CNS diseases, SC5b-9 was not detected in eight of 11 and was present in low concentrations in the remaining three patients (mean, 0.28 μg/ml; range, 0 to 1.7 μg/ml). The finding of SC5b-9 complexes in the CSF of patients with GBS and MS suggests that terminal complement components may participate in the tissue-damaging processes in these diseases.

AB - A quantitative enzyme-linked immunosorbent assay was used to measure the concentration of fluid-phase complement C5b-9 complexes (SC5b-9) in the cerebrospinal fluid (CSF) of 14 patients with acute monophasic Guillain-Barre Syndrome (GBS), 21 patients with multiple sclerosis (MS), and 11 patients with noninflammatory central nervous system (CNS) diseases. SC5b-9 complexes were detected in the CSF of 13 of 14 patients with acute GBS (mean, 3.08 μg/ml; range, 0 to 7.1 μg/ml) and 16 of 21 patients with MS (mean, 1.83 μg/ml; range, 0 to 7.5 μg/ml). In the control group of patients with noninflammatory CNS diseases, SC5b-9 was not detected in eight of 11 and was present in low concentrations in the remaining three patients (mean, 0.28 μg/ml; range, 0 to 1.7 μg/ml). The finding of SC5b-9 complexes in the CSF of patients with GBS and MS suggests that terminal complement components may participate in the tissue-damaging processes in these diseases.

UR - http://www.scopus.com/inward/record.url?scp=0022568932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022568932&partnerID=8YFLogxK

M3 - Article

C2 - 3711661

AN - SCOPUS:0022568932

VL - 136

SP - 4456

EP - 4459

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -